Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Multidisciplinary Cancer Congress
ECCO 15 - ESMO 34 will take place at the ICC Berlin - Internationales Congress Centrum, Messedamm 22, D-14055 Berlin, Germany (http://www.icc-berlin.de) from Sunday 20 September to Thursday 24 September 2009.
generic viagra online
Endocrine Society Issues Position Statement On Endocrine-Disrupting Chemicals
Interest and concern about possible health threats posed by endocrine-disrupting chemicals (EDCs) is on the rise, yet there is currently no comprehensive coordinated approach to regulating EDCs in the United States. To address this emerging public health issue, The Endocrine Society today released a new position statement outlining the public health concerns of exposure to EDCs and proposing a series of recommendations for revising current policy and generating new policy on EDCs.
News of the day
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals" PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. The Company intends to market the product under the trade name Next Choice(TM) and plans to launch the product shortly. For the 12-months ending March 2009, PLAN B(R) had total U.S. sales of approximately $123 million, of which approximately ten percent are attributable to prescription sales, according to IMS sales data. PLAN B(R) over-the-counter (O.T.C.) new product exclusivity expires on August 24, 2009.
Sexual Health

Budesonide/formoterol Plus Tiotropium Improves The Quality Of Life Of Patients With Severe COPD

Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease (COPD) show that budesonide/formoterol (Symbicort®: AstraZeneca) plus tiotropium (Spiriva™: Boehringer Ingelheim Limited) significantly improves disease control and patients" quality of life.1,2 The study known as CLIMB, compared 12 weeks treatment with budesonide/formoterol (400/12 mcg one inhalation twice-daily) plus tiotropium (18 ÷µg one inhalation once daily) vs. tiotropium alone plus placebo. "Combined inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) therapy with budesonide/formoterol (Symbicort®) is indicated for COPD patients with a forced expiratory volume in 1 second (FEV1) Notes An estimated 3.7 million people in the UK have COPD; COPD is the 5th biggest killer in the UK; around 30,000 people in the UK die from COPD each year, which is more than from bowel cancer, breast cancer or prostate cancer.6 References 1. Welte T, et al. Budesonide/formoterol added to tiotropium improves the management of COPD patients. American Thoracic Society International Conference, San Diego, USA, 15-20 May 2009; Abst 953775. 2. Welte T, et al. Budesonide/formoterol added to tiotropium is well tolerated and reduces the risk of severe exacerbations in COPD patients. American Thoracic Society International Conference, San Diego, USA, 15-20 May 2009; Abst 953763. 3. Symbicort 400/12® Summary of Product Characteristics, December 2008. 4. Miravitlles M et al. Patient"s perception of exacerbations of COPD - The PERCEIVE study. Respir Med 2007; 101: 453-60. 5. "Unleash the life within..." a patient"s perspective of living with Chronic Obstructive Pulmonary Disease (COPD) Survey. Sponsored by AstraZeneca UK Ltd. 6. British Lung Foundation. Invisible Lives. Chronic Obstructive Pulmonary Disease (COPD) - finding the missing millions, November 2007. AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009